Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute kidney injury

Clinical trials in AKI: is the end in sight?

Nature Reviews Nephrology volume 12, pages 263–264 (2016)Cite this article

Subjects

Clinical trials in patients with acute kidney injury (AKI) have been stymied by a lack of consensus on suitable renal-specific end points. In a recent analysis, Grams et al. suggest that a sustained 30–40% reduction in estimated glomerular filtration rate after hospital discharge might be a suitable intermediate end point for AKI clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Change in glomerular filtration rate over time following the onset of AKI.

References

  1. Grams, M. E. et al. Candidate surrogate end points for ESRD after AKI. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2015070829 (2016).

  2. International Society of Nephrology. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2, 1–138 (2012).

  3. Coresh, J. et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311, 2518–2531 (2014).

    Article  Google Scholar 

  4. Palevsky, P. M. et al. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin. J. Am. Soc. Nephrol. 7, 844–850 (2012).

    Article  Google Scholar 

  5. Okusa, M. D. et al. Design of clinical trials in acute kidney injury: a report from an NIDDK workshop — prevention trials. Clin. J. Am. Soc. Nephrol. 7, 851–855 (2012).

    Article  Google Scholar 

  6. Molitoris, B. A. et al. Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. Clin. J. Am. Soc. Nephrol. 7, 856–860 (2012).

    Article  Google Scholar 

  7. Go, A. S. et al. The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol. 11, 22 (2010).

    Article  Google Scholar 

  8. Weisbord, S. D. et al. Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin. J. Am. Soc. Nephrol. 8, 1618–1631 (2013).

    Article  Google Scholar 

  9. Matthay, M. A. & Liu, K. D. New strategies for effective therapeutics in critically ill patients. JAMA 315, 747–748 (2016).

    Article  CAS  Google Scholar 

  10. Liu, K. D. & Glidden, D. V. Clinical trials for acute kidney injury: design challenges and possible solutions. Curr. Drug Targets 10, 1190–1195 (2009).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

K.D.L. has received funding from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (grant number 5R01DK098233) and from the National Heart, Lung, and Blood Institute.

Author information

Authors and Affiliations

  1. School of Medicine, University of California, 505 Parnassus Avenue, San Francisco, 94143, California, USA

    Monica Parks

  2. Divisions of Nephrology and Critical Care, Departments of Medicine and Anesthesia, University of California, 533 Parnassus Avenue, Room U408, San Francisco, 94143, California, USA

    Kathleen D. Liu

Authors
  1. Monica Parks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen D. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen D. Liu.

Ethics declarations

Competing interests

K.D.L. has consulted for ZS Pharma, Achaogen, Chemocentryx, and Durect. She has received compensation for travel from the American Society of Nephrology. She is an Amgen stockholder. M.P. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parks, M., Liu, K. Clinical trials in AKI: is the end in sight?. Nat Rev Nephrol 12, 263–264 (2016). https://doi.org/10.1038/nrneph.2016.35

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2016.35

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing